Global Market Direct’s pharmaceuticals report, “Accera, Inc. - Product Pipeline Review - 2013” provides data on the Accera, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Accera, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Accera, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Accera, Inc. - Brief Accera, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Accera, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Accera, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Accera, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Accera, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Accera, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Accera, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Accera, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Accera, Inc. and identify potential opportunities in those areas.
Table Of Contents
Accera, Inc. - Product Pipeline Review - 2013 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Accera, Inc. Snapshot 4 Accera, Inc. Overview 4 Key Information 4 Key Facts 4 Accera, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Accera, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Accera, Inc. - Pipeline Products Glance 9 Accera, Inc. - Early Stage Pipeline Products 9 Pre-Clinical Products/Combination Treatment Modalities 9 Accera, Inc. - Drug Profiles 10 AC-0523 10 Product Description 10 Mechanism of Action 10 RandD Progress 10 AC-8632 11 Product Description 11 Mechanism of Action 11 RandD Progress 11 Accera, Inc. - Pipeline Products By Mechanism of Action 12 Accera, Inc. - Recent Pipeline Updates 13 Accera, Inc. - Locations And Subsidiaries 14 Head Office 14 Accera, Inc., Recent Developments 15 Accera, Inc.- Press Release 15 Apr 09, 2013: Accera And University of Miami Collaborate To Study Axona For Cognitive Impairment In Patients With Multiple Sclerosis 15 Oct 05, 2010: Accera Receives FDA Acceptance Of IND Application For AC-1204 For Alzheimer's Disease 15 Mar 10, 2010: Accera Announces New Data On Ketone Body Therapy For Alzheimer's Disease Treatment 16 Financial Deals Landscape 18 Accera, Inc., Deals Summary 18 Accera, Inc., Pharmaceuticals and Healthcare, Deal Details 19 Venture Financing 19 Accera Raises Additional US$15 Million In Venture Financing 19 Accera Secures US$11 Million In Venture Financing 20 Accera Secures US$35 Million In Series C Financing 21 Acquisition 22 Nestle Health Science Completes Acquisition Of Minority Stake In Accera 22 Appendix 24 Methodology 24 Coverage 24 Secondary Research 24 Primary Research 24 Expert Panel Validation 24 Contact Us 25 Disclaimer 25
List of Tables
Accera, Inc., Key Information 4 Accera, Inc., Key Facts 4 Accera, Inc. - Pipeline by Indication, 2013 6 Accera, Inc. - Pipeline by Stage of Development, 2013 7 Accera, Inc. - Monotherapy Products in Pipeline, 2013 8 Accera, Inc. - Pre-Clinical, 2013 9 Accera, Inc. - Pipeline Products By Mechanism of Action, 2013 12 Accera, Inc. - Recent Pipeline Updates, 2013 13 Accera, Inc., Deals Summary 18 Accera Raises Additional US$15 Million In Venture Financing 19 Accera Secures US$11 Million In Venture Financing 20 Accera Secures US$35 Million In Series C Financing 21 Nestle Health Science Completes Acquisition Of Minority Stake In Accera 22
List of Figures
Accera, Inc. - Pipeline by Indication, 2013 6 Accera, Inc. - Pipeline by Stage of Development, 2013 7 Accera, Inc. - Monotherapy Products in Pipeline, 2013 8